Related Experiment Video
Updated: Mar 2, 2026
07:11
Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis
Published on: May 23, 2025
1.0K
Mazindol: a risk factor for pulmonary arterial hypertension?
Eric Konofal1, Cherine Benzouid2, Christophe Delclaux3
1Pediatric Sleep Disorders Center, Hôpital Robert Debré, Assistance Publique - Hôpitaux de Paris (APHP), Paris, France.
Sleep Medicine
|May 20, 2017
Summary
Mazindol, a CNS stimulant, is being reconsidered for narcolepsy and ADHD. While rare, potential risks like pulmonary arterial hypertension (PAH) require updated understanding for patient safety.
Area of Science:
- Pharmacology
- Neuroscience
- Cardiovascular Medicine
Background:
- Mazindol is a tricyclic CNS stimulant blocking dopamine and norepinephrine reuptake.
- Withdrawn in 1999, its withdrawal was unrelated to efficacy or safety concerns.
- Other anorexics were linked to pulmonary arterial hypertension (PAH), but mazindol-associated PAH is extremely rare.
Purpose of the Study:
- To provide an updated understanding of mazindol's benefits and risks.
- To evaluate mazindol's potential in treating narcolepsy and attention-deficit/hyperactivity disorder (ADHD).
Main Methods:
- Literature review of existing studies on mazindol.
- Analysis of reported cases of adverse events, specifically PAH.
- Assessment of pharmacological profile for potential therapeutic applications.
Main Results:
- Mazindol's mechanism involves blocking dopamine and norepinephrine reuptake.
- Pulmonary arterial hypertension (PAH) is a rare adverse event associated with mazindol.
- Growing interest in mazindol for narcolepsy and ADHD treatment.
Conclusions:
- Mazindol's efficacy and safety profile warrant re-evaluation for new indications.
- Careful risk-benefit assessment is crucial for patients considered for mazindol therapy.
- Further research is needed to confirm safety and efficacy in narcolepsy and ADHD populations.
Related Concept Videos
01:30Pulmonary Hypertension: Classification and Pathogenesis
724
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
724
01:24Drug Toxicity: Risk factors
60
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
60
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
671
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
671
01:22Mitral Stenosis I: Introduction
966
Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...
966
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
556
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
556
01:20COPD: Pathogenesis and Clinical Features
2.0K
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
2.0K